To perform a cost analysis comparing the cost of robotassisted radical cystectomy (RARC) with open RC (ORC) in a UK tertiary referral centre and to identify the key cost drivers.
Introduction
Primary bladder cancer is a serious worldwide health risk and is increasing in incidence across the elderly population [1, 2] . It is now the seventh most common type of cancer in the UK [1] and the ninth most common cancer in the world, with >429 800 new cases diagnosed globally each year [3] . The current 'gold standard' treatment for muscle-invasive bladder cancer is open radical cystectomy (ORC) with pelvic lymph node dissection [4, 5] . However, using such an extensive extirpative procedure amongst an ageing population, with multiple co-morbidities, results in higher levels of patient morbidity and mortality [1, 6] . Bladder cancer accounts for 3% of all cancers in the UK [7] and it is one of the most expensive cancers for the NHS to treat, costing £65 million annually [8] .
There has been a paradigm shift towards minimally invasive surgery across all surgical specialities. Since its first description [9] , robot-assisted RC (RARC) has become an increasingly popular method for the treatment of bladder cancer. From 2004 to 2010, the number of RARCs underwent a 21-fold increase from 0.6% to 12.8% [5] ; however, RARC with full intracorporeal reconstruction is offered in relatively few large-volume UK centres. RARC is associated with decreased hospital length of stay (LOS), reduced blood loss and analgesic requirements, fewer complications, and faster postoperative recovery times [10, 11] .
Annual costs of cancer services to the NHS are £5 billion [12] . With the ever-increasing burden of healthcare costs across the NHS, both national and local commissioning groups are reviewing all aspects of healthcare provision. Despite apparent advantages of robot-assisted surgery, a recent NHS England consultation process has challenged the routine commissioning of robot-assisted surgery for bladder cancer in England due to the perceived high economic costs [13] . Urological surgeons continue to argue that cost-drivers, such as the reduced LOS and decreased blood transfusion, may offset the additional equipment costs and therefore make a robotic approach more favourable [14, 15] .
The present study investigates the immediate surgical outcomes from a series of patients who previously underwent ORC at this institution [16] with a contemporary cohort treated with RARC. The aim was to assess and compare the cost of an ORC with a RARC using data from a single high-volume UK tertiary robotic centre.
Patients and Methods
All surgical cases were performed at the Bristol Urological Institute (BUI). The BUI is a large-volume tertiary referral centre in the South-West of England. The BUI began its RARC service in 2010. Currently, RARC with intracorporeal reconstruction represents the standard surgical approach for patients with invasive bladder cancer, irrespective of cancer stage or patient co-morbidity.
Information for ORC was obtained from a previously published series of patients [16] . This cohort of patients consisted of 68 consecutive patients who underwent ORC at the BUI after the introduction of an enhanced recovery programme. Data on RARC was obtained from the BUI's prospectively updated institutional database for RC. This cohort of patients consisted of 221 consecutive patients undergoing RARC with full intracorporeal reconstruction between December 2011 and December 2016. Information from the BUI database was cross-referenced with the North Bristol NHS Trust electronic transfusion record. Statistical analysis of the groups was performed using a non-paired t-test for numerical variables and chi-squared and Fisher's exact test for dichotomous and categorical variables.
Data including average LOS, transfusion rate, readmission rate, complication rate, and operative time (OT) were obtained. Complications were stratified as per the modified Clavien-Dindo system [17] [18] [19] [20] . Each grade was assigned extra days in hospital (for example, Clavien-Dindo Grade II led to 2 additional days in hospital, Clavien-Dindo Grade IV led to 4 extra days etc.), as in previous analyses [21] . A cost decision tree model was used to consolidate these costs.
The da Vinci â S robot (Intuitive Surgical Inc., Sunnyvale, CA, USA) was calculated at a purchase cost provided by Ramsay et al. [21] in their health technology analysis. Two models were assumed: i) institution responsible for purchase and annual maintenance costs, or ii) institution responsible for only annual maintenance (robot donated through charitable funds). A 10-year amortisation was assumed; consistent with the expected duration of use of the system [21] . The cost was added to an annual maintenance contract from Intuitive Surgical, Inc. It was assumed the robot would perform 400 cases/year, which is consistent with this institution's actual volume.
Surgical costs were obtained from hospital administrator supplied data and from respective suppliers. This included costs such as robotic instruments, open instruments, sutures and packed red blood cells (RBCs). Consumable equipment costs were calculated from typical case usage by surgeons at this institution. OT for RARC was taken as an average of consecutive operations at this institution for both ORC and RARC. Cost of the operating room per hour was calculated using data from ISD (Information Services Division) Scotland Theatre Services R142X [22] . This data source was chosen for its granularity, as it included separate costs for surgical, anaesthetic and nursing staff, anaesthetic drugs, cleaning and sterilisation, and overheads such as electricity. In total, it provided a cost figure (£1100/h), which is comparable to overall figures reported in England [23] .
Blood transfusion and LOS costs were also included. Probability of transfusion and average transfusion rates were obtained from an institutional database and electronic transfusion records. The mean LOS was 8.76 days for RARC and 12.50 days for ORC, as previously published [24] . The cost of one baseline elective in-patient stay was taken from NHS reference costs 2015/16 [25] . All procedures in the NHS have an expected LOS (the 'trim point'), with additional days in hospital being charged as excess days (£306/day). RARC has no published trim point, so in this analysis average RARC LOS was taken as the trim point and additional days stayed in hospital for ORC were charged as excess days [25] .
The linear cost model was constructed using Microsoft Excel 2016 (Microsoft Corp., Redmond, WA, USA). The decision tree analysis, Monte Carlo analysis and sensitivity analysis were run in TreePlan, SimVoi and SensIt, respectively (TreePlan Software, San Francisco, CA, USA). Institutional research approval was granted.
Results
In total, 221 patients underwent RARC (7.7% orthotopic neobladder; 91.4% ileal conduit) vs 68 patients who underwent ORC (100% ileal conduit). The demographics of the two groups showed no statistical difference for age, gender or cancer stage and grade. On average, RARC patients were younger at operation (69 vs 71 years). The median American Society of Anesthesiologists (ASA) score for both ORC and RARC patients was 2. Table 1 summarises important patient characteristics.
The mean operating time (OT) was 4.4 h for RARC and 3.2 h for ORC. As a result, operating room costs were £4815.52 and £3496.44 for RARC and ORC, respectively. The mean LOS was lesser for RARC (8.8 vs 12.5 days); correspondingly the cost of LOS after each procedure was £3749.00 for RARC and £4894.77 for ORC. The complication rate was 29.4% for RARC and 44.1% for ORC (stratified by Clavien-Dindo classification). The average per-case cost of complications, using the method as proposed by Ramsay et al. [21] , was £203.08 for ORC and £138.11 for RARC, respectively. No RARC operations were converted to ORC. The base model assumed that 2 units of RBCs were given in 30.9% of ORC and 9.7% of RARC to derive a per-case cost of transfusion; no other blood products were transfused. Finally, including equipment costs, the total average cost of one RARC procedure was £12 449.87. If the initial capital outlay is avoided via charitable donation this costs decreases to £12 106.12. One ORC procedure costs £10 474.54, which means that RARC is 18.9% more expensive than ORC. The constituent components of the cost model are summarised in Table 2 . As hypothetical exploration, an analysis was run to compare only ileal conduit RARC operation (n = 202) to the ORC cohort. In total, the ileal conduit RARC cost was £12 244.15, 16.9% more expensive than ORC.
Sensitivity Analysis
Annual RARC case volume, post-RARC LOS, complication rates and OT were varied to examine their impact on total RARC cost. There were two scenarios in which RARC became cheaper than ORC -when OT was <156 min or when hospital LOS was <4.14 days. OT was compared between patients who had their surgery in the most recent year of 2016 (n = 50) and those who had it previously (n = 170); the mean (SD) OT was 230.99 (49.02) min and 274.59 (66.91) min, respectively (P < 0.05). No other scenario where RARC was cheaper than ORC was found (Fig. 1) . A tornado plot was created to visualise which of the factors influenced cost the most (Fig. 2) . This analysis reveals the cost difference between ORC and RARC is influenced most by OT, LOS and case volume, in order of magnitude.
Monte Carlo Analysis
Monte Carlo simulation, a form of probabilistic analysis, was used (10 000 iterations) to propagate uncertainty in input parameters such as LOS, OT, cases per volume and rate of complications in order to present the results of this analysis with their associated uncertainty. The standard deviation (SD) for RARC cost figure was £1579.44 and for ORC was £1326.31. A two-tail t-test was run to test for a significant difference between the costs of RARC vs ORC. The difference in cost was significant at the 1% level.
Quality of Life Requirement
Cost utility analyses are used in the UK to inform commissioning decisions. The National Institute for Health and Care Excellence (NICE), the special authority in the UK charged with health technology assessments, has a threshold of £20 000-30 000 per quality adjusted life year (QALY) [26] If it is assumed that QoL is exactly one postoperatively (a QoL of one is perfect, there is no limitation in any dimension of life), it follows that the 0.0988 difference in QALY comes only from an improvement in the patient's length of life by 5 weeks and 1 day. It is not as easy to quantify improvements in QoL. The QoL is a subjective measure quantified by patient questionnaires such as the EuroQoL five Dimensions questionnaire (EQ-5D) or the Short-Form Six-Dimension (SF-6D) health index [27, 28] . For example, if a patient returns to normal physical functioning 3 weeks after RARC and 3 months after ORC, there is a significant improvement in physical activity, but attaching an associated numerical value also depends on the patient's perceived gain and therefore must be measured appropriately with a patient questionnaire. 
Discussion
The present study aimed to determine the cost of one RARC and compare it to the cost of an ORC in a single UK institution. There is evidence that robotic approaches can accelerate recovery time, reduce blood loss and reduce complication rates [29] , although robotic surgical systems are associated with significantly higher material costs [30] . Robotic surgical platforms are frequently used by subspecialities within urology and between other surgical specialities. It is therefore extremely challenging to accurately apportion the capital costs of a robotic surgical system for a particular procedure [31] . Furthermore, a robotic surgical system delivering RARC would inevitably be associated with high surgical volumes, which has been shown to offset the high-associated costs [21] . However, such an analysis can inform and facilitate effective decision-making when commissioning services, and to ensure the effective use of scarce public resources. Importantly, the present analysis was performed in a country where the future commissioning of RARC remains uncertain.
The main finding of the present study is that one average RARC procedure costs £12 449.87, which is 18.9% more expensive than ORC. The cost components included in the present study include: initial capital cost, LOS, operative cost, complication rate, transfusion rate, readmission rate, and equipment cost. One of the major differences between an ORC and a RARC is the initial capital outlay for the robotic surgical platform. In the UK, most robotic systems have been financed via external funding, typically from charitable donations [16] . However, at this institution the system was financed directly by the hospital trust. Therefore, the higher figure is used as the basis for the subsequent discussion.
Another significant cost associated with robot-assisted surgery is operative room costs. Total operative cost is composed of surgeon and nursing staff fees, allocated costs and total OT. The present study shows that the operative room costs for RARC was 1.38-times more expensive than ORC. Whilst many of the factors contributing to this remain constant between the two approaches, OT is significantly different. Previous studies have shown that RARC, on average, has a longer OT than ORC, with mean OTs of 4.41 and 3.20 h, respectively [15, [32] [33] [34] [35] [36] . This parameter is determined by surgeon experience and skill level and therefore more experienced centres are likely to have lower OTs, resulting in lower costs [37] . In this centre, the mean (SD) OT for RARC operations performed in the year 2016 was 3.85 (0.82) h (n = 50), which was significantly different to RARC operations performed prior to 2016 [mean (SD) 4.58 (1.12) h; n = 170; P < 0.05)], suggesting continued optimisation of surgeon and theatre staff technique. Sensitivity analysis revealed that an OT of 2.60 h (156 min) is required to achieve equivalent costs between operative approaches. Although it is possible to achieve console times of 2-3 h, a total OT of 2.6 h including anaesthetic time, port placement, docking and theatre changeover represents a significant challenge.
An additional significant cost-driver is LOS. Sensitivity analysis revealed that a reduction in post-RARC hospital LOS from the mean (SD) of 8.76 (6.79) days to 4.41 days would make RARC cheaper than ORC. In a German cohort, Gandaglia et al. [32] reported the mean post-RARC LOS as 13 days, in the USA, Rhee et al. [38] reported 11 days, and Canada Galich et al. [39] reported a median LOS of 8 days. Furthermore, patients submitted to the national BAUS database for 2016, had a mean LOS of 8 days with a median of 6 days. Although, RARC consistently shows a reduction in LOS compared to ORC, achieving a mean average of 4.41 days represents a significant challenge. Nonetheless, a synergistic effect with a concurrent reduction in OT cannot be ignored. Similarly to other reports [14, 35, 36, 40] , the present study has shown that robotic approaches lead to savings in hospital LOS, transfusion rates, and complication rates. However, these savings are offset by the significant equipment costs associated with RARC, which are 2.4-times more expensive when compared to ORC (Table 2 ). This is due to the current market monopoly that exists within the robotic industry, where Intuitive Surgical Inc. remains the sole supplier of robotic equipment [41] . In addition to the presence of a market monopolist, suppliers must also abide by stringent international regulations. This incurs a significant cost and poses a large barrier to entry for new market entrants.
The total cost of RARC and ORC in the present study is considerably lower in comparison to similar studies from North America [35, 40] . Multiple reasons can be attributed to this. Firstly, the cost of complications, which contributes 1.3% to the average RARC cost and 2.4% to the average ORC cost, is calculated by assigning extra days of hospital stay per the Clavien-Dindo grade of complication. For example, it is assumed that a patient with Clavien-Dindo Grade II would stay in hospital for 2 extra days and a patient with ClavienDindo Grade IV would stay in hospital for 4 extra days. This methodology, used by Ramsay et al. [21] in Health Technology Assessments for the NICE, may under-represent the true cost of a complication and its treatment. High-grade complications in particular can require costly operative and radiological interventions together with admission to intensive care units, which is not captured with this approach. Despite this, the present study remains important for understanding the relative difference in cost between the two operative approaches; however, the authors acknowledge this methodology may reduce the generalisability of the cost figures. Furthermore, the present study uses a 10-year amortisation period, consistent with the expected life of the robotic equipment in a British setting, whereas the studies from North America have used a 7-year depreciation period instead. This has meant the per case cost of robotic equipment is over £140 cheaper in the present analysis when compared to other reports. In addition, the institution in this report is a high-volume centre performing >400 robotic procedures per year. The effect of this is to further reduce the cost of robotic equipment in the analysis, resulting in a percase cost of £343.75. In comparison, Martin et al. [40] used an annual case volume of 300 cases and Lee et al. [35] used 361 cases.
Typically, sensitivity analysis has been used to measure uncertainty in cost-effective analyses [42, 43] . However, as Baltussen et al. [44] highlight, there are problems with this approach; interpretation remains arbitrary because there are no guidelines to determine robust evidence, and variation of uncertain parameters one at a time carries a risk that interactions between parameters may not be captured [45] . In the present study, with the intention of overcoming these issues, a Monte Carlo simulation with 10 000 iterations was used and showed the difference between the cost results was statistically significant at the 1% level.
The primary limitation of the present study is the use of a single institution for data analysis. Furthermore, the data from robotic procedures comes in part from procedures performed during the learning curve. Data published online as part of the national BAUS data for 2016, shows further significant improvements in LOS, OT, transfusion rates, and complication-rates [46] . In addition, there are several costs not included in the present analysis. Firstly, patients undergoing ORC at this institution would routinely be admitted to a high-dependency unit (HDU) postoperatively. Examination of RARC data reveals a 25% reduction in postoperative HDU admission, with a significant number of patients being transferred to a ward environment postoperatively. Although, this represents a significant cost implication, the duration of HDU admission in the ORC group is incomplete and has therefore not been included.
Secondly, the economic impact of surgery must consider costs incurred beyond the immediate perioperative period, such as those related to rehabilitation and additional surgery. Recent studies using national Hospital Episodes Statistics data have shown significant reductions in long-term health utilisation and downstream cost savings of robot-assisted approaches for prostate and kidney cancer [31, 47] . Based on clinical observations alone, it is the authors' view that this would be replicated for bladder cancer also, with patients tending to have earlier return to normal activities, and a decrease in the incidence of longer-term complications, such as ureteric stenosis or parastomal hernias with RARC (unpublished results).
Finally, the present study should have incorporated utility data in order to create a cost-utility analysis. However, the current medical literature lacks detailed UK-based utility data for bladder cancer. In part, this is because patient-recorded outcome measures and quality-of-life assessment tools specific to patients undergoing RARC are presently lacking, but are being developed within this institution. The absence of such data from the present study represents an additional limitation. However, the authors believe that the dramatic improvements in patient recovery and return to normal activities routinely seen in our practice would translate into the quality-of-life improvements required to demonstrate at the very least equivalent costs, but quite possibly an improvement in favour of RARC.
Conclusion
Despite the challenges in calculating procedure-specific costs in robot-assisted surgery, the present study aims to provide data regarding the comparative costs of ORC vs RARC from a UK centre. Based on the analysis from this institution, 
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